Conference News

New Genetic Test Targets Rare X-Linked Movement Disorder

A targeted assay, presented at AMP 2025, identifies disease-specific TAF1 variants that standard panels often miss.

Share

Original Source(s)

New Genetic Test Targets Rare X-Linked Movement Disorder

A targeted assay, presented at AMP 2025, identifies disease-specific TAF1 variants that standard panels often miss.

  • by Conexiant News Staff

  • November 15, 2025

  • 2 min

Related Content

AI Models Predict CNS Tumors From Spinal Fluid

At AMP 2025, a South Korean research team outlined a multimodal approach that integrates CSF, DNA, and MRI data to enable early, noninvasive tumor classification.

Artificial Intelligence in Health Care: The Ethical Frontier

At AMP 2025, Takunda Matose, PhD, urged pathologists to consider the limitations of big data and probabilistic reasoning to maximize AI’s benefits for clinical outcomes.

Streamlining VUS Classification in Clinical Genomics

New variant classification standards and data-sharing initiatives will help laboratories and clinicians focus on actionable variants.